Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 548110
Title Leveraging the medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
Author(s) Nyagwange, James; Awino, Elias; Tijhaar, Edwin; Svitek, Nicholas; Pelle, Roger; Nene, Vishvanath
Source International Journal for Parasitology: Drugs and Drug Resistance 9 (2019). - ISSN 2211-3207 - p. 80 - 86.
DOI https://doi.org/10.1016/j.ijpddr.2019.01.002
Department(s) WIAS
Cell Biology and Immunology
Publication type Refereed Article in a scientific journal
Publication year 2019
Keyword(s) Dasatinib - East coast fever - Malaria box - Medicines for malaria venture - Theileria parva
Abstract

Chemotherapy of East Coast fever, a lymphoproliferative cancer-like disease of cattle causing significant economic losses in Africa, is largely dependent on the use of buparvaquone, a drug that was developed in the late 1980's. The disease is caused by the tick-borne protozoan pathogen Theileria parva. Buparvaquone can be used prophylactically and it is also active against tropical theileriosis, caused by the related parasite Theileria annulata. Recently, drug resistance was reported in T. annulata, and could occur in T. parva. Using a 3 H-thymidine incorporation assay we screened 796 open source compounds from the Medicines for Malaria Venture (MMV) to discover novel chemicals with potential inhibitory activity to T. parva. We identified nine malaria box compounds and eight pathogen box compounds that inhibited the proliferation of F100TpM, a T. parva infected lymphocyte cell line. However, only two compounds, MMV008212 and MMV688372 represent promising leads with IC 50 values of 0.78 and 0.61 μM, respectively, and CC 50 values > 5 μM. The remaining compounds exhibited a high degree of toxicity (CC 50 values < 1.09 μM) on the proliferation of bovine peripheral blood mononuclear cells stimulated with concanavalin A. We also tested the anti-cancer drug, dasatinib, used in the chemotherapy of some leukemias. Dasatinib was as active and safe as buparvaquone in vitro, with an IC 50 of 5 and 4.2 nM, respectively, and CC 50 > 10 μM. Our preliminary data suggest that it may be possible to repurpose compounds from the cancer field as well as MMV as novel anti-T. parva molecules.

Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.